The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...

The company said that envudeucitinib met all the primary and secondary endpoints in both trials. ・Across both trials, the ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.